Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332455 · ClinicalTrials.gov registry record · Phase 1
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
A Phase 1 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT07332455: Recruiting Phase 1 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.
NCT07332455 is a Phase 1 study of Neoplasms Prostate that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 54 participants, below the 3,099-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07332455, a Phase 1 study of Neoplasms Prostate, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Conditions Studied
Interventions
- DRUG GSK5471713
Study Locations (3)
Michigan
- GSK Investigational Site - Grand Rapids
Utah
- GSK Investigational Site - West Valley City
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2030-03-26 |
| Phase | Phase 1 |
What NCT07332455 shows while recruiting
NCT07332455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 3,099-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Neoplasms Prostate appearing as the primary indexed condition, and to 1 intervention - of which GSK5471713 is the first listed.
NCT07332455 reports a single indexed study location in Michigan, Utah, Quebec.
Frequently Asked Questions
What is clinical trial NCT07332455 about?
NCT07332455 is a clinical study titled "First-Time-in-Human Study of GSK5471713 in Adults With mCRPC". This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
What is the current status of trial NCT07332455?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2026-02-10. Estimated completion is 2030-03-26.
What conditions does trial NCT07332455 study?
This clinical trial studies the following conditions: Neoplasms Prostate.
What interventions are being tested in trial NCT07332455?
The interventions under investigation include: GSK5471713 (DRUG).
Who is sponsoring clinical trial NCT07332455?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07332455 being conducted?
This trial has 3 study locations across Michigan, Utah, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
RECRUITING · Phase 1
-
MRI/Ultrasound Fusion Guided Prostate Cryotherapy
RECRUITING
-
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
RECRUITING
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
COMPLETED · Phase 4
-
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI